Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;10(2):577-582.
doi: 10.3892/ol.2015.3262. Epub 2015 May 25.

Clinical benefits of metformin in gynecologic oncology

Atsushi Imai  1 , Satoshi Ichigo  2 , Kazutoshi Matsunami  2 , Hiroshi Takagi  2 , Keigo Yasuda  3
Affiliations

Clinical benefits of metformin in gynecologic oncology

Atsushi Imai et al. Oncol Lett. 2015 Aug.

Abstract

Evidence has suggested that diabetes may contribute to the initiation and progression of specific types of cancer. Metformin, a biguanide, has become the preferred first-line therapy for the treatment of type 2 diabetes. Metformin is inexpensive, has a proven safety profile and is able to be safely combined with additional antidiabetic agents. In addition to the well-established antidiabetic effects of metformin, there has also been notable interest in its antitumor properties. The present review discusses the emerging role of metformin as an example of an existing drug, used worldwide in the treatment of diabetes, which has been demonstrated to exert significant in vitro and in vivo anticancer activities and has thus been investigated in clinical trials. In gynecologic oncology, metformin has been suggested to exhibit significant treatment efficacy against endometrial cancer. Three studies have demonstrated the potential therapeutic effects of metformin on the survival outcome of patients with ovarian cancer and in ovarian cancer prevention. However, this evidence was based on observational studies. Metformin has been shown to exert no statistically significant beneficial effect on cervical cancer incidence or mortality. By cancer site, the current limited insights highlight the need for clinical investigations and better-designed studies, along with evaluation of the effects of metformin on cancer at other sites.

Keywords: cervical cancer; diabetes mellitus; endometrial cancer; insulin; metformin; ovarian cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proposed antitumor effects of metformin. AMPK, adenosine monophosphate kinase; LKB1, liver kinase B1; IGF1, insulin-like growth factor 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Noto H, Goto A, Tsujimoto T, Osame K, Noda M. Latest insights into the risk of cancer in diabetes. J Diabetes Investig. 2013;4:225–232. doi: 10.1111/jdi.12068. - DOI - PMC - PubMed
    1. Sen S, He Y, Koya D, Kanasaki K. Cancer biology in diabetes. J Diabetes Investig. 2014;5:251–264. doi: 10.1111/jdi.12208. - DOI - PMC - PubMed
    1. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 2009;27:2170–2176. doi: 10.1200/JCO.2008.17.5935. - DOI - PMC - PubMed
    1. Chodick G, Heymann AD, Rosenmann L, Green MS, Flash S, Porath A, Kokia E, Shalev V. Diabetes and risk of incident cancer: A large population-based cohort study in Israel. Cancer Causes Control. 2010;21:879–887. doi: 10.1007/s10552-010-9515-8. - DOI - PubMed
    1. Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Investig. 2012;2:24–33. doi: 10.1111/j.2040-1124.2011.00183.x. - DOI - PMC - PubMed

LinkOut - more resources